You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Management of Upper GI Cancers in Canada: Exploring Immunotherapy Options Earlier in the Disease Course

  • Authors: Ronan Kelly, MD; Christine Brezden-Masley, MD; Howard Lim, MD
  • CPD Released: 4/6/2022
  • Valid for credit through: 4/6/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for medical oncologists, hematologists, surgeons, radiologists, and HCPs involved in the management of upper GI cancers in Canada.

The goal of this activity is for the learner to improve their knowledge and confidence on the latest data for advanced/metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma as well as adjuvant treatment for stage II or III esophageal or GEJ cancer, how to interpret this for clinical practice and what the potential impact may be for the management of patients, particularly for learners who are treating physicians in Canada.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical benefit of immunotherapy and chemotherapy as first-line therapy for the treatment of advanced gastric, GEJ, and esophageal adenocarcinoma
    • Rationale for immunotherapy as adjuvant for stage II or III esophageal or GEJ cancer 
  • Demonstrate greater confidence in their ability to
    • Use immunotherapy for the management of patients with upper gastrointestinal (GI) cancers


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Faculty

  • Ronan Kelly, MD

    Director of Oncology
    Charles A. Sammons Cancer Center
    Dallas, Texas, United States

    Disclosures

    Consultant or advisor for: Astellas; AstraZeneca; Bristol Myers Squibb Company; Daiichi Sankyo; Eisai; EMD Serono; Ipsen; Lilly; Merck; Novartis; Phillips; Takeda
    Speaker or member of speakers bureau for: AstraZeneca; Bristol Myers Squibb Company; Daiichi Sankyo
    Research funding from: Bristol Myers Squibb Company; Lilly

  • Christine Brezden-Masley, MD

    Medical Oncologist
    Mount Sinai Hospital
    Associate Professor
    University of Toronto
    Medical Director Cancer Program
    Sinai Health System
    Director
    Marvelle Koffler Breast Centre
    President, Canadian Cardio-Oncology Network
    Toronto, Canada

    Disclosures

    Consultant or advisor for: Agendia; Amgen; AstraZeneca; Bristol Myers Squibb Company; Gilead; Hoffman-La Roche; Lilly; Merck; Mylan; Myriad; Novartis; Pfizer; Sanofi; Seagen Inc., formerly Seattle Genetics, Inc.; Taiho 
    Research funding from: Amgen; Astellas; AstraZeneca; Hoffman-La Roche; Lilly; Novartis; Pfizer; Taiho 

  • Howard Lim, MD

    Clinical Associate Professor
    University of British Columbia
    Competency Based Medical Education Co-Lead PGME UB
    Vancouver, Canada

    Disclosures

    Consultant or advisor for: AstraZeneca; Bristol Myers Squibb Company; Eisai; Ipsen; Merck; Roche; Taiho
    Research funding from: Astellas; AstraZeneca; Bristol Myers Squibb Company; Roche

Editors

  • Keisha Peters, MSc

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Keisha Peters, MSc, has no relevant financial relationships.

  • Eloise Ballard, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Disclosure: Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer:

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Management of Upper GI Cancers in Canada: Exploring Immunotherapy Options Earlier in the Disease Course

Authors: Ronan Kelly, MD; Christine Brezden-Masley, MD; Howard Lim, MDFaculty and Disclosures

CPD Released: 4/6/2022

Valid for credit through: 4/6/2023

processing....

Pre-Assessment Survey

Before you begin, please take this brief survey.